Comparative Pharmacology
Head-to-head clinical analysis: ATACAND versus TEVETEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND versus TEVETEN.
ATACAND vs TEVETEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker